Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$26.12 - $34.07 $940 - $1,226
-36 Reduced 0.16%
22,932 $781,000
Q1 2024

May 14, 2024

SELL
$26.64 - $40.31 $80,506 - $121,816
-3,022 Reduced 11.63%
22,968 $808,000
Q4 2023

Feb 12, 2024

BUY
$19.95 - $31.0 $112,936 - $175,491
5,661 Added 27.85%
25,990 $750,000
Q3 2023

Nov 13, 2023

SELL
$21.33 - $59.42 $1.65 Million - $4.59 Million
-77,168 Reduced 79.15%
20,329 $465,000
Q2 2023

Aug 11, 2023

BUY
$34.33 - $62.11 $568,882 - $1.03 Million
16,571 Added 20.48%
97,497 $5.59 Million
Q1 2023

May 12, 2023

BUY
$26.01 - $48.69 $1.84 Million - $3.45 Million
70,811 Added 700.06%
80,926 $3.05 Million
Q4 2022

Feb 13, 2023

SELL
$24.14 - $30.37 $23,150 - $29,124
-959 Reduced 8.66%
10,115 $270,000
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $23,630 - $35,472
1,063 Added 10.62%
11,074 $313,000
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $9,317 - $20,300
472 Added 4.95%
10,011 $217,000
Q1 2022

May 16, 2022

BUY
$36.25 - $52.02 $8,410 - $12,068
232 Added 2.49%
9,539 $382,000
Q4 2021

Feb 14, 2022

SELL
$43.27 - $65.72 $4.33 Million - $6.58 Million
-100,065 Reduced 91.49%
9,307 $441,000
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $1.68 Million - $2.11 Million
31,313 Added 40.11%
109,372 $6.2 Million
Q2 2021

Aug 17, 2021

BUY
$45.13 - $64.99 $3.29 Million - $4.74 Million
72,993 Added 1440.84%
78,059 $4.48 Million
Q1 2021

May 17, 2021

SELL
$29.77 - $84.85 $1.14 Million - $3.25 Million
-38,330 Reduced 88.33%
5,066 $321,000
Q4 2020

Feb 16, 2021

BUY
$25.66 - $34.55 $233,967 - $315,026
9,118 Added 26.6%
43,396 $1.46 Million
Q3 2020

Nov 16, 2020

BUY
$22.51 - $30.11 $142,600 - $190,746
6,335 Added 22.67%
34,278 $937,000
Q2 2020

Aug 14, 2020

BUY
$12.65 - $29.57 $353,478 - $826,274
27,943 New
27,943 $756,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.